arrow
J

James Davis

Medical University of South Carolina
H指数:91
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium

氟达拉滨淋巴细胞清除暴露与伊达比特-维克鲁塞尔治疗后复发性/难治性多发性骨髓瘤的毒性相关:来自美国骨髓瘤免疫治疗联盟的真实世界经验

2025-09-170
PREAI
Review of Paleoproterozoic tectonics in the southern West African Craton: Insights from multi-disciplinary data integration

西非克拉通南部古元古代构造研究综述:多学科数据融合的启示

2025-06-010
OAAI
An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell

基于内皮激活和应激指数(EASIX)的预测模型,用于B细胞成熟抗原(BCMA)导向的嵌合抗原受体(CAR)T细胞疗法后的神经毒性及细胞因子释放综合征(CRS)

BLOOD
IF23.1
2024-11-050
PRE
Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

地塞米松用于管理与teclistamab相关的CRS,适用于复发/难治性多发性骨髓瘤患者。

BLOOD
IF23.1
2024-11-050
PRE
Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

干细胞增强(SCB)对嵌合抗原受体T细胞(CAR-T)相关血液学毒性的疗效:一项多中心真实世界研究经验(针对复发/难治性多发性骨髓瘤患者)

BLOOD
IF23.1
2024-11-050
PRE